<DOC>
	<DOCNO>NCT01855061</DOCNO>
	<brief_summary>The purpose study determine whether possible predict response chemotherapy patient metastatic cancer treat irinotecan determine mutational profile tumor .</brief_summary>
	<brief_title>Biomarker Development Response Prediction DNA Mutational Analysis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Patients metastatic solid tumor fail least one line palliative chemotherapy irinotecan na√Øve . 2 . Patients , per local protocol , eligible palliative treatment ( standard care ) irinotecan . 3 . Measurable metastatic lesion ( ) , accord RECIST 1.1 criterion . 4 . Radiological measurable metastatic lesion ( ) histological biopsy safely obtain : 1 . Patients safely accessible metastasis . 2 . Patients know bleed disorder ( hemophilia ) bleeding complication biopsy , dental procedure surgery . 3 . Patients use anticoagulant medication time biopsy : aspirin derivative , NSAID 's , coumarines , platelet function inhibitor , heparin ( include LMWHs ) oral factor Xa inhibitor allow , unless medication either safely stop counteract . 4 . Adequate coagulation status day biopsy measure : PTT &lt; 1.5 x ULN APTT &lt; 1.5 x ULN Platelet count 100 x 10*9 / L high PTINR &lt; 1.6 HB &gt; 6 5 . Biopsies perform least four week last bevacizumab administration . 5 . Patients age 18 year , willing able comply protocol judge investigator sign informed consent . Patients meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Feasibility study</keyword>
	<keyword>Sequence analysis , DNA</keyword>
	<keyword>Biological marker</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Pharmacokinetics SN-38</keyword>
	<keyword>Carboxylesterase activity within metastasis</keyword>
</DOC>